Chimeric Therapeutics (CHM) H2 2025 earnings summary

Executive summary

• Achieved significant clinical milestones in CDH17 and CORE-NK trials, including successful patient dosing and positive early responses in acute myeloid leukemia and blood cancer studies.

• Strengthened leadership with the appointment of a new CEO and a renowned haematologist as Non-Executive Director.

• Advanced intellectual property position with a new US patent for CDH17 CAR construct, valid through at least 2039.

Financial highlights

• Reported net loss of $10.4 million for FY2025, an improvement from $12.5 million loss in FY2024, attributed to reduced headcount and lower administrative expenses.

• Revenue from ordinary activities was $3.97 million, down 100% from the prior year.

• Cash reserves increased to $5.76 million at year-end, up from $3.05 million in FY2024.

• Net tangible liabilities per ordinary security improved to (0.45) cents from (1.09) cents.

Outlook and guidance

• Focus remains on executing clinical development plans and advancing cell therapy programs for oncology.

• No short-term revenue expected from development programs; long-term value creation anticipated upon successful outcomes.